Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
Research from P. Norman and co-authors yields new data on life sciences
October 15th, 2008
According to recent research published in the journal Expert Opinion on Therapeutic Patents, "The p38 kinases have long been recognized as potentially valuable targets in the development of novel anti-inflammatory therapies." "Benzoylpyridinone p38 inhibitors are described that incorporate cell-targeting fragments. The latter groups are appended to the active inhibitor to provide groups that undergo specific esterase cleavage inside the cell, thereby enhancing kinase inhibitory activity," wrote P. Norman and colleagues. The researchers concluded: "These applications represent the first disclosure of Chroma's synthetic strategy in targeting...
Source: Medical Patent Law Weekly (2008-10-15)
|
